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INTRODUCTION
Sleep disorders are highly prevalent among patients with 
Parkinson disease. However, there are also reports of Par-
kinson patients experiencing a beneficial effect of sleep. Upon 
awaking in the morning, many patients experience an im-
proved mobility as if they are in a medication-induced “on” 
state, contrary to what would be expected after a night without 
medication. This intriguing phenomenon is known as “sleep 
benefit.” 1 Some Parkinson patients are even able to delay or 
skip their morning dose of medication because of this sleep 
benefit.2 According to questionnaire studies, the prevalence 
of sleep benefit is consistently reported to be quite high, with 
33% to 55% of Parkinson patients reporting to experience sleep 
benefit.2,3
Studies using objective measures of sleep benefit are limited 
in number so far. A few studies assessed motor performance 
using the Unified Parkinson’s Disease Rating Scale (UPDRS) 
motor scale.4,5 In the Högl study, there was no difference in 
morning function between patients with and without subjec-
tive sleep benefit. However, comparisons between evening and 
morning status showed an improvement in motor function in 
those patients reporting sleep benefit, and a deterioration in 
patients without.5
Although widely used, the UPDRS strongly depends on 
the observer and is time-consuming. Attractive alternative 
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measures for motor fuction are available, such as the pegboard 
dexterity test, which is a fast and sensitive instrument to ob-
jectively and quantitatively evaluate motor dysfunction in Par-
kinson disease.6–8 Additionally, bradykinesia can be quantified 
using an alternating finger tapping task (digitography).9 Both 
tests correlate well with the UPDRS III.7,10 Therefore, the peg-
board dexterity test and finger tapping task appear to be excel-
lent tools to assess the motor correlates of sleep benefit. In this 
study, we used these quantitative motor tasks to assess possible 
changes in motor function after a period of sleep in Parkinson 
patients. We compare and describe sleep-related changes in 
motor function in patients that report to experience sleep ben-
efit, those who do not and in healthy elderly controls. We focus 
not only on nighttime sleep but also on daytime naps, and as-
sess the quality and characteristics of the preceding period of 
sleep (using polysomnography) and subjective ratings of motor 
function and mood/vigilance to examine whether these are re-
lated to changes in motor functioning.
METHODS
Patients
Patients were recruited from a cohort of 240 Parkinson 
patients who completed both a questionnaire and a diary on 
sleep benefit. Patients filled out a daily symptom diary before 
and directly after sleep for 7 consecutive days, in which they 
subjectively rated different aspects of their motor functioning 
(see measures section for more details). A night with a positive 
change of at least one point (better functioning in the morning 
than in the evening) was regarded as a “sleep benefit-night.” 
The same approach was used for daytime naps. Patients were 
classified as having sleep benefit, when sleep benefit was 
present after ≥ 2 nights or 2 naps during the 7-day period. 
We alo used a questionnaire that asked patients whether or 
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not they experienced any sleep benefit, based on the recently 
revised definition of sleep benefit, as follows: “Sleep ben-
efit is the experience of a temporary decrease in Parkinson’s 
symptoms upon awakening after a period of sleep (night or 
daytime), before drug intake; the patient is feeling as good as 
‘on’ (or better).” 11 More details on both the diary and question-
naire can be found in the paper describing the results of these 
instruments.12
We estimated a required number of subjects based on an 
effect size of one-third of the effect size to differentiate be-
tween healthy controls and early diagnosed Parkinson pa-
tients.8 With a correlation between consecutive pegboard test 
results of 0.93,7 an α value of 0.05 and β of 0.8, this yielded 
a required group size of approximately 17 evaluable subjects. 
We were able to include 18 Parkinson patients who clearly 
reported to experience a subjective improvement in motor 
functioning after night and/or daytime sleep. In addition, we 
selected 20 patients who reported no improvement at all after 
sleep.
We included patients with idiopathic Parkinson disease, 
defined according to the UK Brain Bank criteria, Hoehn & 
Yahr stage I-III. Exclusion criteria included current major psy-
chiatric diagnosis, deep brain surgery for Parkinson disease, 
neurological disease other than Parkinson disease and chronic 
daily use of hypnotics. All patients were used to taking an af-
ternoon nap, so they felt able to sleep during the nap period in 
the experiment.
Healthy Controls
Twenty healthy controls participated. These controls were 
recruited in the older healthy population (40–75 years old). 
Controls were not necessarily habitual nappers; however, they 
all indicated that they were able to sleep during the day. Exclu-
sion criteria were current neurologic or psychiatric diagnosis 
and chronic daily use of hypnotics.
Consent
The study was approved by the institutional medical ethical 
committee. All participants gave their written informed con-
sent before participating. Participants received a financial com-
pensation for their participation in this study.
Study Design
Procedure
Figure 1 shows the study design. In the early evening, sub-
jects arrived at the sleep lab. First they were trained extensively 
in the pegboard dexterity task and finger tapping task. Before 
bedtime, a test session was completed (test 1). All test sessions 
included the pegboard dexterity task, finger tapping task, and 
subjective rating scales on motor functioning and mood/vigi-
lance, described below. The order of administration was coun-
terbalanced across subjects.
Subjects spent the night at the sleep lab. On awakening in 
the morning, a test session was completed (test 2). For all post-
sleep measures, the tasks were administered 15 minutes after 
awakening to reduce the possible influence of sleep inertia. 
Later in the morning, a neuropsychological test battery was 
completed.
In the early afternoon, all subjects took an afternoon nap 
directly followed by a test session after awakening (test 4). We 
applied a crossover design, in which the reference examination 
(test 3) was done either before the nap or after an additional pe-
riod of active wakefulness, when possible sleep benefit effects 
had disappeared. The order of examination was randomized 
and counterbalanced in all groups. The results of test 3 did not 
differ, either when this test was performed before the nap or 
after rest. Therefore, these data were pooled in the analyses.
Night Sleep
Subjects went to bed at 23:00 and slept until they woke up 
spontaneously to reduce the possible effects of residual sleepi-
ness (sleep inertia) on morning testing. However, when not 
yet awake at 07:30, they were awakened by the experimenter. 
After 06:00, when a subject woke up and did not fall asleep 
again within 15 minutes, the night sleep period was terminated 
and post sleep tasks were started.
Nap
For the afternoon nap, subjects had a 90-min nap opportu-
nity. The subjects slept until they woke up spontaneously or 
were awakened by the experimenter when the 90 min were 
over. When a subject slept a cumulative minimum of 15 min 
Figure 1—Schematic overview of the study design. At every test session the pegboard task, task switching task and motor and mood/vigilance rating scales 
were obtained. During the night and afternoon nap, sleep was monitored by polysomnography and video. During the neuropsychological examination the 
Mini mental state examination, Frontal assessment battery, Dutch adult reading test, and Beck depression inventory were obtained.
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and did not fall asleep again within 15 min, the nap period was 
terminated and post sleep tasks were started.
Rest Period
During the rest period, subjects could perform their normal 
afternoon activities for 90 min. They were, for example, al-
lowed to talk to the experimenter, read a book, or take a short 
walk, but they had to stay at the lab. Subjects were not allowed 
to sleep during the rest period.
Medication
On the day of arrival in the sleep lab for the night of the 
study, patients did not take their Parkinson medication after 
13:00. When they arrived in the sleep lab, they were thus al-
ready in the “off’’ state. After the pre-night test sessions, pa-
tients took their normal bedtime dose of Parkinson medication 
before the night (23:00), to increase the probability of a normal 
night of sleep. When patients did not take medication at bed-
time, they postponed their evening medication (i.e., dinner 
time) to the night. This was the case for 10 patients (55.5%) 
with sleep benefit and 6 (30%) patients without sleep benefit. 
All dopaminergic medication was converted into the L-dopa 
equivalent dose (LED), using the formula described by Tom-
linson et al.13 In the sleep benefit group, 16 patients were using 
levodopa and 9 patients (also) used dopamine agonists. In the 
group without sleep benefit, 19 patients used levodopa and 9 
patients (also) used dopamine agonists. Both patients and con-
trols were allowed to take other prescribed drugs. During the 
stay at the sleep lab, subjects were not allowed to drink any 
caffeine or alcohol containing drinks.
Measures
Motor Tasks
In the modified Perdue pegboard task, the time needed to 
place eight pegs from one hole to the next using one hand was 
measured. In the finger tapping task, the number of taps in 
30 sec and the number of errors (pressing the 2 keys simultane-
ously) were registered. These finger tapping scores were auto-
matically converted into a number of cycles (Hz). Both tasks 
were performed with both hands separately using a computer-
based device (part of the At-Home Testing Device, Intel, cour-
tesy of the Kinetics Foundation).9 Subjects practiced the tasks, 
alternating both hands, until scores reach asymptotic levels, 
with a minimum of 4 practice trials.
Subjective Assessment of Functioning after Sleep
The symptom diary was based on the SCOPA Diary Card 
(SCOPA DC),14 a validated instrument to assess changes in 
motor functioning during the day. Patients indicated on a 
4-point Likert scale how well they could perform 3 activities, 
i.e., walking, changing position, and using their hands, a higher 
score indicating more difficulties in performance. These ac-
tivities were proven to give a reliable indication of general 
motor functioning.14 The scores on different items were added 
to obtain one subjective motor score. In addition, the ques-
tion on sleep quality from the SCOPA DC was used and we 
added an extra question on feeling rested upon awakening. 
Mood/vigilance ratings were obtained using a 16-item visual 
analogue scale containing 3 factors: alertness, calmness, and 
contentedness.15
Neuropsychological Tasks
To asses baseline neuropsychological functions, a battery 
of tasks was used: Beck Depression Inventory (BDI),16 Mini-
Mental State Examination (MMSE),17 Frontal Assessment Bat-
tery (FAB)18; and premorbid intelligence levels were assessed 
using the Dutch version of the National Adult Reading Test 
(DART).19,20
Polysomnography
All sleep was polysomnographically monitored using 
a dedicated recording system (Compumedics Grael PSG, 
Compumedics, USA). PSG registration included standard 
6-channel electroencephalography and electromyography of 
m. submentalis. Sleep stages were scored according to the 
AASM 2007 criteria21 using ProFusion software (ProFusion 
sleep 3 [build 392], Compumedics, USA). The main sleep 
outcomes were total sleep time, sleep efficiency, and sleep 
latency.
Analyses
All analyses were performed separately for night sleep and 
afternoon nap. The motor tasks and subjective measures on 
motor function and mood/vigilance were analyzed using re-
peated measures ANOVA, with the between-subject factor 
“group” (subjective sleep benefit, no sleep benefit, healthy con-
trols) and one within-subject factor “sleep” (before sleep vs. 
after sleep). Sleep benefit was defined as a group by sleep in-
teraction in these ANOVA models. Correlation analyses were 
performed using partial correlations controlled for “group.” 
Alpha was set to 0.01 in all analyses regarding multiple com-
parisons. All analyses were performed in SPSS version 20 for 
Windows.
RESULTS
Characteristics of the participants, baseline motor scores, 
and scores on the neuropsychological examination can be 
found in Table 1. The patient groups did not differ from each 
other, except that patients with sleep benefit tended to have 
longer disease duration (t = 2.56, P = 0.015). There was a 
trend towards higher LED in the sleep benefit group (t = 2.046, 
P = 0.05). However, there were no between group differences 
in the proportions of patients using extended release L-dopa, 
dopamine agonists, or COMT inhibitors. Patients had higher 
scores on the Beck depression inventory than the healthy 
controls (healthy controls vs. sleep benefit t = 4.84, P < 0.001, 
healthy controls vs. no-sleep benefit t = 6.18, P < 0.001 ). The 
no-sleep benefit group scored slightly lower on the Frontal 
Assessment Battery (FAB) than healthy controls (t = −3.33, 
P = 0.002); however, the group reporting sleep benefit showed 
no significant differences on the FAB when compared to 
healthy controls.
There were no between group differences in total sleep time, 
sleep stages, sleep efficiency, or sleep latency for night sleep 
nor afternoon nap (Table 2). There were also no differences in 
subjective ratings of sleep quality and feeling rested after sleep 
(night sleep and nap).
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Motor Tasks
The results of the motor tasks can be found in Figure 2. 
There was a small overall effect of night sleep on the pegboard 
task (F1,55 = 9.695, P = 0.003); subjects were on average slower 
in the morning. However, for the finger tapping tasks, there 
was no overall difference in evening and morning performance. 
Patients were slower than healthy controls on both tasks (Peg-
board: F2,55 = 16.938, P < 0.001, Finger tapping: F2,55 = 406.5, 
P < 0.001). For both tasks the overnight change in performance 
did not differ between the groups (no group*sleep interaction).
For the afternoon nap, pa-
tients were again slower than 
healthy controls (Pegboard: 
F2,55 = 15.331, P < 0.001, Finger 
tapping: F2,55 = 450.3, P = 0.002). 
There was no significant overall 
effect of sleep on both tasks, nor 
was there a group difference in 
the change in performance (no 
group*sleep interaction). There 
was no correlation between 
sleep time or efficiency and the 
difference in scores on either of 
the motor tasks, for both night 
sleep and the afternoon nap, 
nor did any of the sleep archi-
tecture measures show such an 
effect.
We did a subgroup analysis 
with only the 11 patients that 
reported subjective sleep ben-
efit in both the sleep benefit 
questionnaire and symptom 
diary, hypothesizing that these 
patients had the clearest sub-
jective sleep benefit. However, 
when comparing this subgroup 
with patients without subjective 
sleep benefit and healthy con-




Patients had higher (worse) 
scores in the motor symptom 
diary than healthy controls 
(night: F2,55 = 22.4, P < 0.001; 
healthy controls vs. sleep ben-
efit P < 0.001, healthy controls 
vs no-sleep benefit P = 0.001; 
nap: F2,55 = 15.2, P < 0.001; 
healthy controls vs. sleep ben-
efit P < 0.001, healthy controls 
vs. no-sleep benefit P = 0.01, see 
also Figure 3). Patients in the 
sleep benefit group tended to 
have higher (worse) diary scores 
than patients in the no sleep benefit group (night: P = 0.012 nap: 
P = 0.031, Figure 3). We did not find a main effect of sleep on 
subjective motor scores after either night sleep or afternoon 
nap. There was also no group difference in the over-sleep 
change in subjective motor function (no group*sleep interac-
tion). The correlation between the subjective motor score and 
the pegboard test, calculated using all available timepoints (be-
fore and after night and daytime sleep) was rp = 0.43 (P < 0.001) 
and between the subjective motor score and the finger tapping 
test was rp = −0.30 (P < 0.0001).
Table 1—Descriptive demographics and clinical disease characteristics of study sample.
Patients Healthy
ControlsSleep Benefit No Sleep Benefit
N 18 20 20
Men, n (%) 6 (35%) 14 (70%) 11 (58%)
Age, years 61.0 ± 5.9 63.2 ± 7.8 58.5 ± 7.5
Disease duration, years 7.7 ± 4.3 4.6 ± 2.7 na
Age onset, years 52.3 ± 7.7 57.0 ± 7.7 na
LED, mg/day 777 ± 384 542 ± 270 na
MMSE 28.18 ± 2.2 27.75 ± 1.9 28.84 ± 1.2
FAB 16.06 ± 1.5 15.25 ± 2.3 17.16 ± 0.9
DART, IQ estimate 111.18 ± 17.7 108.85 ± 17.5 105.84 ± 18.4
BDI 10.12 ± 6.5 8.75 ± 3.8 2.68 ± 2.4
Baseline PGT, sec 19.5 ± 3.9 18.5 ± 3.3 14.3 ± 1.2
Baseline FTT, cycles 75.2 ± 27.2 75.4 ± 44.7 94.2 ± 26.4
Values are presented as mean ± standard deviation unless otherwise specified. The two patient groups did 
not significantly differ on the presented variables, except for disease duration. This is in line with previous 
findings on sleep benefit. LED, levodopa equivalent dose; MMSE, Mini Mental State Examination; FAB, Frontal 
Assessment Battery; DART, Dutch Adult Reading Test; BDI, Beck Depression Inventory; PGT, pegboard task; 
FTT, finger tapping task.
Table 2—Sleep parameters.
Patients Healthy
ControlsSleep Benefit No Sleep Benefit
Night 
Total sleep time, min 356 ± 96 366 ± 98 406 ± 44
 N1, % of TST 12.5 ± 16.1 8.0 ± 5.1 7.8 ± 3.8
 N2, % of TST 48.5 ± 12.55 51.3 ± 8.7 50.2 ± 11.0
 N3, % of TST 26.4 ± 11.3 25.8 ± 10.3 24.7 ± 11.0
 REM, % of TST 12.6 ± 8.8 14.8 ± 6.8 18.1 ± 6.1
Sleep efficiency, % 75.4 ± 17.8 76.8 ± 18.6 83.3 ± 6.3
Sleep latency, min 32 ± 64 25 ± 31 12 ± 10
Nap
Total sleep time, min 46 ± 24 45 ± 26 50 ± 19
 N1, % of TST 19.2 ± 19.1 19.2 ± 24.1 16.3 ± 20.3
 N2, % of TST 55.2 ± 19.7 53.3 ± 25.0 49.9 ± 21.6
 N3, % of TST 22.9 ± 23.7 25.1 ± 25.3 30.7 ± 22.3
 REM, % of TST 2.7 ± 6.0 2.4 ± 7.4 3.0 ± 6.7
Sleep efficiency, % 58.5 ± 28.5 58.1 ± 26.1 65.6 ± 20.5
Sleep latency, min 8.6 ± 7.4 11.6 ± 10.7 8.3 ± 8.2
Values are presented as mean ± standard deviation. There we no significant differences between the sleep 
benefit and no-sleep benefit groups and between both of these groups and controls. TST, total sleep time.
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Mood/Vigilance Rating Scales
There was no effect of sleep on the mood/vigilance scales 
for night sleep or afternoon nap. There was also no group 
difference in the over-sleep change in mood/vigilance (no 
group*sleep interaction). The healthy controls felt better than 
both patient groups (P < 0.005 for all scales, see also Table 3); 
however, the patient groups did not differ. The mood/vigilance 
rating scores did not correlate with the scores on the motor 
tasks.
DISCUSSION
The existence of subjective sleep benefit in Parkinson disease 
has been reported repeatedly in the literature.1–4,22–25 However, 
only few studies assessed whether sleep benefit is also associ-
ated with an objective improvement in motor symptoms. Here 
we used two quantitative motor tasks to assess sleep benefit 
in Parkinson patients. We showed that there was no objective 
sleep-related improvement in Parkinson signs in patients that 
declared to experience subjective sleep benefit. As expected, 
patients with and without subjective sleep benefit were slower 
on the quantified motor tasks than healthy controls. However, 
patients with or without sleep benefit did not differ in task per-
formance after sleep.
We examined whether the lack of objective sleep benefit 
could be explained by the quality of the intervening sleep epi-
sodes. If “sleep benefit” is a real phenomenon, qualitatively 
better sleep should result in greater benefit for patients. Objec-
tive and subjective sleep quality did not differ between groups, 
and both nighttime sleep and afternoon naps were similar 
among groups. This shows that all groups achieved a good 
amount of sleep, excluding the possibility that lack of actual 
sleep explained the negative findings. Some studies suggested 
that sleep benefit might be related to poorer sleep.2,5,26 How-
ever, we found no support for this hypothesis. Taken together, 
Figure 2—Motor task scores. (A) Pegboard task night. (B) Pegboard task nap. (C) Finger tapping night. (D) Finger tapping nap. SB, sleep benefit.
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our results suggest that the quality of the preceding period of 
sleep does not determine the occurrence of sleep benefit either 
way, at least not for the range of sleep qualities achieved in this 
experimental setting.
Patients with subjective sleep benefit may also simply feel 
better after sleep. However, we did not find differences in sub-
jective mood/vigilance and subjective sleep quality among pa-
tient groups. Although there was no change in subjective motor 
scores after sleep in patients with or without subjective sleep 
benefit, patients with sleep benefit tended to rate their motor 
signs as worse than patients without sleep benefit. So, the diary 
scores were not simply a reflection of mood/vigilance at the 
moment of testing. Moreover, the quantitative motor perfor-
mance correlated with the subjective motor evaluation whereas 
the other subjective measures did not correlate with quatitative 
motor performance.
During the study, patients were not allowed to take Par-
kinson medication, so they were in the “off” state. We chose 
this approach because medication could mask possible sleep 
benefit. Furthermore, the exact influence of medication on 
motor functioning is difficult to define. Because of the large 
variability in medication we decided to test all patients without 
medication. There was a trend 
towards more medication use 
in patients with sleep benefit, 
so they possibly experienced a 
greater medication withdrawal 
effect. However, this was not re-
flected by the quantitative motor 
scores, nor by the the mood/
vigilance scores.
The leading hypothesis on 
the mechanism of sleep benefit 
states that dopamine storages 
in nigral neuronal terminals are 
replenished during sleep.2,5,11 
According to this hypothesis, 
the presence of sleep benefit 
should have been more clear 
without medication, as its effect would not be masked by do-
paminergic medication. As we did not find an objective sleep 
benefit effect, this hypothesis seems less likely. It could also 
be that sleep benefit is an overnight medication effect, for 
example caused by extended release L-dopa or longer acting 
dopamine agonists. In our patients, there was a trend toward 
more daily L-dopa equivalent medication use in the sleep 
benefit group, but the use of different types of medication did 
not differ between patient groups. However, we acknowledge 
that our study was designed to assess the effect of sleep and 
not the effect of medication. Therefore, the exact influence 
of medication on (fluctuations in) motor function remains 
to be studied formally using a design dedicated to diurnal 
medication effects.
As sleep benefit is a temporary phenomenon,2,4,11 we de-
cided not to use an additional clinical examination to assess 
Parkinson signs. When performing an extensive examination 
such as the UPDRS, possible sleep benefit effects could have 
disappeared before finishing the complete test. As the aim of 
this study was to assess differences in objective motor per-
formance, we chose to use two quick, quantitative motor tests, 
which do correlate well with the UPDRS.7,10
Figure 3—Subjective symptom diary scores. SB, sleep benefit.
Table 3—Subjective measures.
Sleep Benefit No Sleep Benefit Healthy Controls
Pre-sleep Post-sleep Pre-sleep Post-sleep Pre-sleep Post-sleep
Night
Alertness 4.4 ± 0.3 4.4 ± 0.3 3.5 ± 0.3 3.8 ± 0.4 2.3 ± 0.5 2.4 ± 0.3
Calmness 4.1 ± 0.6 3.5 ± 0.6 3.7 ± 0.4 3.8 ± 0.5 2.1 ± 0.4 1.9 ± 0.3
Contentedness 3.2 ± 0.4 3.2 ± 0.4 3.2 ± 0.4 3.0 ± 0.4 1.5 ± 0.2 1.5 ± 0.2
Nap
Alertness 3.7 ± 0.3 3.4 ± 0.5 3.0 ± 0.4 3.3 ± 0.4 1.4 ± 0.3 2.4 ± 0.4
Calmness 3.9 ± 0.5 3.1 ± 0.5 3.1 ± 0.4 3.0 ± 0.4 1.3 ± 0.3 1.4 ± 0.2
Contentedness 2.7 ± 0.3 2.6 ± 0.4 2.7 ± 0.3 2.7 ± 0.4 1.1 ± 0.2 1.4 ± 0.2
Values are presented as mean ± standard error. The possible mood/vigilance rating scores range from 0 (very 
alert/calm/contented) to 10 (not alert/calm/contented at all). 
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We evaluated only one night of sleep and one daytime nap. 
There could be some day-to-day variation in the occurrence 
of sleep benefit. None of the patients reported improvement 
every night in the 7-day screening diary used for recruitment. 
So, even the patients with clear subjective sleep benefit had 
nights without improvement in the symptom diary. A longitu-
dinal study including more nights and naps could account for 
this variation. There was some variability in results; in both 
patient groups there were patients who improved and patients 
who worsened on the motor tasks. However, the individual dif-
ferences in performance over sleep were small, and even in the 
healthy control group there were subjects who improved and 
subjects who deteriorated a similar amount after a period of 
sleep. So the observed differences in performance are probably 
not Parkinson-specific, but represent a naturally occurring ef-
fect throughout the population.
It was shown before that patients with subjective sleep ben-
efit sometimes seem to misperceive their motor functioning 
at awakening. Högl et al. reported that “several patients with 
sleep benefit praised their morning mobility as unrestrained 
[…] although their overall appearance and objective evaluation 
using UPDRS were indicative of being in the “off” state.” 5 Our 
results also showed that the subjective experience of sleep ben-
efit did not match actual improvement in motor functioning. 
Our results combined with these previous findings offer fur-
ther evidence that sleep benefit is mainly a subjective phenom-
enon that is not related to a Parkinson-specific improvement 
in motor function. Nevertheless, subjective sleep benefit is 
reported in the literature by a consistently high number of pa-
tients. The origin and underlying mechanism of this subjective 
sleep benefit should be the focus of future research.
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